Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.62 |
| ▸ | NAAA | Q02083 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873765 | 0.85 | EPHX2 (0.55) | EPHX2CYP2C9PRMT5WDR77TAAR1 | |
| SCHEMBL13873793 | 0.84 | EPHX2 (0.57) | EPHX2CYP2C9NAMPTPRMT5WDR77 | |
| SCHEMBL13873586 | 0.81 | EPHX2 (0.66) | EPHX2CYP2C9NAAANAMPT | |
| SCHEMBL13873835 | 0.79 | EPHX2 (0.63) | EPHX2CYP2C9NAMPTPRMT5WDR77 | |
| SCHEMBL13873594 | 0.78 | EPHX2 (0.58) | EPHX2CYP2C9CYP2J2 | |
| SCHEMBL13873827 | 0.78 | EPHX2 (0.53) | EPHX2CYP2C9NAMPTPRMT5WDR77 | |
| SCHEMBL13873589 | 0.77 | EPHX2 (0.61) | EPHX2CYP2C9NAAANAMPTCYP2J2 | |
| SCHEMBL13873774 | 0.77 | EPHX2 (1.00) | EPHX2CYP2C9P2RX7CYP2J2ACACB | |
| SCHEMBL13873587 | 0.76 | EPHX2 (0.62) | EPHX2CYP2C9NAAANAMPT | |
| SCHEMBL13873862 | 0.76 | MEN1 (0.54) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| WO-2007106705-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885CYP2C9 477/4885NAAA 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.